Covishield Covid-19 Vaccines
- All
- News
- Videos
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
AstraZeneca Drops Covid Vaccine Weeks After Rare Side Effect Report
AstraZeneca has initiated a global withdrawal of its COVID-19 vaccine, days after it was reported that the British pharmaceutical company admitted that the jab can cause rare side effects.
-
"Sympathy Goes Out...": AstraZeneca Amid Vaccine's Side Effects Concerns
Amid concerns regarding potential side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant on Tuesday reiterated its commitment to patient safety.
-
What Is TTS, A Rare Condition Caused By AstraZeneca's Covishield Vaccine
AstraZeneca, a British pharmaceutical giant, has admitted that its Covid-19 vaccine can result ina rare side effectknown as Thrombosis with Thrombocytopenia Syndrome (TTS).T
-
Serum Institute Restarts Manufacturing Of COVID-19 Vaccine Covishield
Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
-
Serum Institute Restarts Production Of Covishield Vaccine After Cases Rise
Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
-
Indian Medical Experts Support Call For Covishield Vaccine Safety Review
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.
-
Serum Institute To Provide 2 Crore Covishield Doses To Centre For Free
The Serum Institute of India has offered two crore doses of Covishield vaccine to the central government free of cost amid a rise in COVID-19 cases in some countries, official sources said today.
-
Covishield Usage As Booster Highest Compared To Other Vaccines: Report
The usage of Covishield has been the highest as the precaution dose for COVID-19 as compared to other vaccines, said Union Health Ministry sources on Tuesday.
-
Corbevax Approved As Booster Dose For Adults Vaccinated With Covaxin, Covishield
The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
-
Covaxin, Covishield Recipients Had Same Infection Rate In 3rd Wave: Study
Seventy per cent of people who received a booster dose of Covid vaccine did not get infected during the third wave, according to a new study that covered around 6,000 people in India.
-
Serum Institute Halts Vaccine Production Over Millions Of Unused Doses
Serum Institute of India Ltd., the world's largest vaccine manufacturer and a key supplier of Covid-19 inoculations to developing countries, has stopped making fresh batches of shots after its stockpile grew to 200 million doses amid a global supply
-
Coronavirus Highlights: Covishield, Covaxin Prices Cut To Rs 225
The prices of Covishield and Covaxin vaccines at private hospitals have been slashed by more than half. This comes a day before the Covid vaccine booster shots become available to all Indian adults.
-
Covishield Dose Gap Reduced To 8-16 Weeks From 12-16
India's apex body on immunisation NTAGI has recommended administering the second dose of COVID-19 vaccine Covishield between eight and 16 weeks after the first dose.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
AstraZeneca Drops Covid Vaccine Weeks After Rare Side Effect Report
AstraZeneca has initiated a global withdrawal of its COVID-19 vaccine, days after it was reported that the British pharmaceutical company admitted that the jab can cause rare side effects.
-
"Sympathy Goes Out...": AstraZeneca Amid Vaccine's Side Effects Concerns
Amid concerns regarding potential side effects associated with the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant on Tuesday reiterated its commitment to patient safety.
-
What Is TTS, A Rare Condition Caused By AstraZeneca's Covishield Vaccine
AstraZeneca, a British pharmaceutical giant, has admitted that its Covid-19 vaccine can result ina rare side effectknown as Thrombosis with Thrombocytopenia Syndrome (TTS).T
-
Serum Institute Restarts Manufacturing Of COVID-19 Vaccine Covishield
Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
-
Serum Institute Restarts Production Of Covishield Vaccine After Cases Rise
Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
-
Indian Medical Experts Support Call For Covishield Vaccine Safety Review
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.
-
Serum Institute To Provide 2 Crore Covishield Doses To Centre For Free
The Serum Institute of India has offered two crore doses of Covishield vaccine to the central government free of cost amid a rise in COVID-19 cases in some countries, official sources said today.
-
Covishield Usage As Booster Highest Compared To Other Vaccines: Report
The usage of Covishield has been the highest as the precaution dose for COVID-19 as compared to other vaccines, said Union Health Ministry sources on Tuesday.
-
Corbevax Approved As Booster Dose For Adults Vaccinated With Covaxin, Covishield
The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
-
Covaxin, Covishield Recipients Had Same Infection Rate In 3rd Wave: Study
Seventy per cent of people who received a booster dose of Covid vaccine did not get infected during the third wave, according to a new study that covered around 6,000 people in India.
-
Serum Institute Halts Vaccine Production Over Millions Of Unused Doses
Serum Institute of India Ltd., the world's largest vaccine manufacturer and a key supplier of Covid-19 inoculations to developing countries, has stopped making fresh batches of shots after its stockpile grew to 200 million doses amid a global supply
-
Coronavirus Highlights: Covishield, Covaxin Prices Cut To Rs 225
The prices of Covishield and Covaxin vaccines at private hospitals have been slashed by more than half. This comes a day before the Covid vaccine booster shots become available to all Indian adults.
-
Covishield Dose Gap Reduced To 8-16 Weeks From 12-16
India's apex body on immunisation NTAGI has recommended administering the second dose of COVID-19 vaccine Covishield between eight and 16 weeks after the first dose.
